

Meet The Developers

The following Montana State University faculty and staff helped create the content of this toolkit:

- Michelle U. Grocke-Dewey, Ph.D. Principal Investigator, Assistant Professor, Health & Human Development, MSU Extension FCS Health & Wellness Specialist
- Alison Brennan, Ph.D. Principal Investigator, Assistant Professor, Health & Human Development, MSU Extension FCS Mental Health Specialist
- Barbara Allen, M.S. Program Director, MSU Extension Associate Specialist
- Jennifer Munter, Program Manager, MSU Extension
- Barbara Watson, Program Coordinator, MSU Extension
 Lori Mayr, FCS Administrative Assistant, MSU Extension

2

Objectives

At the conclusion of this bonus module, participants will:

- Better understand what Opioid Use Disorder (OUD) is
- Learn about the origins of Medication-Assisted Treatment (MAT) for OUD
- Be more familiar with the different OUD treatment options
- Understand the difference between Opioid Treatment Programs (OTP) vs Office-Based Opioid Treatment (OBOT).


<u>)</u> 3

Components of Evidence-Based Care For Opioid Use Disorder (OUD)

Evidence-based care for OUD involves several components:

- Personalized diagnosis and treatment plan tailored to the individual and family
- Long-term management Addiction is a chronic condition with the potential for both recovery and recurrence. Long-term outpatient care is important.
- Access to FDA-approved medications (MAT)
- Effective behavioral interventions delivered by trained professionals
 Coordinated care for QUD and other conditions
- Coordinated care for OUD and other conditions
 Recovery support services, such as mutual aid groups, peer support specialists, and community services

4



5


What is MAT?

Medication-Assisted Treatment uses both medication and therapy in a combined approach to treat Opioid Use Disorder, sustain recovery, and prevent overdose.


The three components of MAT:

- 1. Stabilization in opioid withdrawal management.
- 2. Medication maintenance using one of three FDA-approved
- medications (methadone, buprenorphine, and naltrexone)
- 3. Counseling and behavioral therapies.

4-minute video on MAT







8

MAT Treatment Options for Opioid Use Disorder (OUD)

Opioid Treatment Programs (OTPs) Outpatient treatment services provided in facilities that provide Substance Use Disorder (SUD) treatment. Monthly counseling and medical provider appointments <u>are required</u>.

Prescribe FDA approved MAT medications: methadone, SUBUTEX®(buprenorphine), SUBOXONE[®] (buprenorphine & naloxone) and VIVITROL[®](naltrexone).

These facilities are accredited by SAMHSA/CARF and licensed by the U.S. Drug Enforcement Administration (DEA) to dispense all FDA approved medications.

Initially, patients go to the clinic 6 days a week for evaluation and observed dosing. No limit on the number of patients who can be treated. id Use Disorder (2019-133) 2019)

Office-based Opioid Treatment (OBOT) Outpatient treatment services provided in primary care

Prescribe FDA approved MAT medications: SUBUTEX® (buprenorphine), SUBOXONE® (buprenorphine & naloxone) and VIVITROL® (naltrexone). Not Permitted to Prescribe Methadone.

Provider must have a Drug Addiction Treatment Act (DATA) wavier to serve more than 30 patients. Under 30 patients, providers apply for the waiver but choose Notice of Intent (NOI), which does not require the waiver qualifying training.


Prescriptions are often written for a 28-day supply, up to 5 refills. Patients fill at their pharmacy After one year, providers can apply to increase capacity

to 100 patients. After two years, they can apply to increase capacity to 275 patients.

9

MONTANA

	Common Names of Opioid Pain Medications Used to Treat OUD		
Name	Brand Name	Street Names	
Methadone (oral tablets)	DOLPHINE®, METHADOSE®	Tootsie roll, Red rock, Mud, Dolls	
Buprenorphine (oral tablet, injection, or implant)	SUBUTEX®, (tablet) SUBLOCADE®(injection), PROBUPHINE® (implant)	Sobos, Saboxin, Oranges, Bupe, Box/boxes, Stops, Subs	
Buprenorphine with naloxone (oral tablets)	SUBOXONE®, ZUBSOLV®, BUNAVAIL®	unknown/unspecified	
MONTANA STATE UNIVERSITY EXTENSION			



11

Methadone

- Long-acting opioid agonist.
- Helps to maintain abstinence by reducing opioid cravings and withdrawal symptoms.
- Unlike other opioids, methadone acts much more slowly in the body = reduces euphoric highs and lows while diminishing withdrawal symptoms.
- Only made available through federally-regulated OTPs
 Not all MAT clinics are OTP clinics and therefore cannot prescribe methadone.

12

MONTANA SANT UNIVERSITY

Buprenorphine

Partial agonist = binds to opioid receptors but activates them less strongly than a full agonist (like methadone).

- This suppresses and reduces cravings, lessens withdrawal, and blocks the euphoric effects of opioids.
- When taken as prescribed, it lowers the potential for misuse.
- First medication used to treat OUD that can be prescribed/dispensed in physician offices. $\succ\,$ This significantly increases access to treatment options.
- Buprenorphine in Office-Based Opioid Treatment (OBOT) facilities:
- Must complete specialized training called a Drug Addiction Treatment Act (DATA) or Buprenorphine Waiver Certification if physicians want to serve more than 30 patients.
 IF, under 30 patients, no waiver training is required, however they do have to file a Notice of Intent (NOI) to obtain their waiver training if eventually they choose to
- Notice of Intent (NOI) to obtain their waiver training if eventually they choose to increase to 100 patients after their first year and 275 after year two. **EXCEPTION:** "Three-day Rule" allows practitioners to administer but not prescribe for a
- 72-hour period. Patients must come back daily to receive their dose.

13

Buprenorphine Waiver

The Substance Abuse and Mental Health Services Administration (SAMHSA) provides buprenorphine waiver certifications allowing physicians, **not practicing in a SAMHSA-certified opioid treatment program (OTP)**, to prescribe buprenorphine to OUD patients. SAMHSA-waivered practitioners, who are certified in prescribing buprenorphine, can be found on the SAMHSA website.

https://www.samhsa.gov/medication-assisted-treatment/practitionerprogram-data/treatment-practitioner-locator

Buprenorphine is also administered at SAMHSA certified opioid treatment programs (OTPs). A list of certified and accredited programs can be obtained by visiting the SMAHSHA website.

https://dpt2.samhsa.gov/treatment/directory.aspx

14

Buprenorphine with Naloxone

- Buprenorphine can be combined with naloxone to prevent opioid overdoses.
- Naloxone interferes with (inhibits) the physiological response in the body.
- These medications are called SUBOXONE®, ZUBSOLV®, BUNAVAIL®

For an alphabetical list of SUBOXONE® treatment programs and doctors who prescribe SUBOXONE® in Montana please visit: https://www.opiateaddictionresource.com/treatment/suboxone_treatm

ent_directory/mt_suboxone/

Naltrexone

- Like naloxone, naltrexone is an opioid antagonist.
- Blocks the euphoric and sedative effects of opioids.
- Reduces cravings for opioids.
- Prevents opioids from producing rewarding effects (euphoria).
- Prescribed outside of an Opioid Treatment Program (OTP)


M MONTANA 16



17

MAT Drugs and Side Effects

Drug	Formulation	Side effect
Methadone	Tablet (Dolophine) Oral concentrate (Methadose)	Respiratory depression, heart rhythm problems, low blood pressure, upset stomach, vomiting, constipation, dizziness, light-headedness, sedation, weakness
Buprenorphine (SUBUTEX®)	Patch (Butrans) Intradermal implant (Probuphine) Injection (Sublocade, Buprenex) Sublingual tablet	Constipation, nausea, vomiting, headache, drowsiness, sedation, insomnia, lack of energy, weakness
Buprenorphine/ Naloxone (combination)	Buccal film (Belbuca, Bunavail) Sublingual tablet (Subutex, Zubsolv) Sublingual film (Cassipa, Suboxone)	Constipation, nausea, vomiting, headache, insomnia, lack of energy
Naltrexone	Oral (Revia, Depade) Injectable suspension for extended release (Vivitrol)	Upset stomach, vomiting, diarrhea, stomach pain, headache, anxiety, dizziness, drowsiness, lack of energy, joint and muscle pain
MONTANA STATE UNITED STATE DATE		



Can These Side Effects Cause Impairments in Everyday Life (i.e., work, home)

Side effects will vary depending on the medication, dosage, and duration of treatment.

Workers with safety-sensitive jobs (bus driver, heavy machine operators, dispatchers, etc.) may be subject to restrictions or limits on the job.

Case-by-case determinations by qualified occupational healthcare providers may be necessary.

Medication side effects often diminish over time and should therefore be periodically assessed.

19

Length of MAT Treatment

- Varies depending on medication
- Duration can span from months to years
- Long-term treatment has proven to be more effective in preventing relapse
- Tapering depends on several factors:

 Compliance, tolerance, adverse effects, and progress toward abstinence
 The tapering process can take several months
- Abrupt or premature removal can increase the risk of relapse and/or an overdose

20

Outcomes of MAT

The MAT approach has been shown to:

- Improve patient survival by reducing overdose occurrences
- Increase retention in treatment
- Decrease illicit opioid use and other criminal activity
- · Increase patients' ability to gain and maintain employment
- Improve birth outcomes among pregnant women who have substance use disorders



Types of Intervention Approaches

- Integrated Health Care
- Early Intervention Delivery Method
- Recovery-Oriented Systems of Care Recovery Approach
- Family Support
- Peer-Based Recovery Support

22

MAT: Integrated Health Care Approach

Integrated Health Care: A team of primary care and behavioral health clinicians, working together with patients and families, using a systematic approach to provide patient-centered care for a defined population.

MAT as an integrated approach:

- > Mental health and substance use disorders (SUDs)
- Health behaviors, and how they contribute to:
 - ➤ chronic medical illness,
 - ➢ life stressors and crises,
 - stress-related physical symptoms, and
 - ➤ ineffective patterns of health care utilization.

(Agency for Healthcare Research and Quality).

23

Early Intervention Delivery Method

Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an approach to the delivery of early intervention and treatment to people with substance use disorders and those at risk of developing these disorders.

- S— quick assessment of the severity of substance use and identifies appropriate level of treatment.
- BI—focuses on increasing insight and awareness regarding substance use and motivation toward behavioral change.
- RT—provides those identified as needing more extensive treatment with access to specialty care.

2017 <u>study</u>, 11 programs serving over 1 million people found an 80% reduction in self-reported illicit substance use, including opioid use, following intervention (Connolly & Baaklini, 2021).

Recovery-Oriented Systems of Care (ROSC) Approach

- ROSC: a coordinated network of community-based services and support: > person-centered
- builds on the strengths and resiliencies of individuals, families, and communities

The establishment of ROSC is a relatively new concept in the substance use disorder field.

25

PreventionInterventionTreatmentPost-Treatment• Early screening before onset• Screening • Early• Menu of treatment services• Continuing care • Recovery support services• Continuing care • Recovery support services• Collaborate with other systems (child welfare, Veterans Affairs)• Pre-treatment• Recovery support services• Check-ups• Stigma reduction activities• Recovery services• Alternative services• Check-ups• Stigma reduction activities• Outreach services• Prevention for families and siblings of individuals in treatment• Self-monitoring		very Orien	ted Activity	Examples
before onset • Early • Recovery support • Collaborate with other systems (child welfare, Veterans Affairs) • Pre-treatment • Recovery support • Stigma reduction activities • Recovery • Recovery • Refer to intervention treatment • Outreach services • Self-monitoring	Prevention	Intervention	Treatment	Post-Treatment
	 before onset Collaborate with other systems (child welfare, Veterans Affairs) Stigma reduction activities Refer to intervention treatment 	 Early intervention Pre-treatment Recovery support services Outreach 	 services Recovery support services Alternative services and therapies Prevention for families and siblings of individuals in 	 Recovery support services Check-ups

26





M 🖄

Peer-Based Recovery Support



Peer support activities:

- Advocating for people in recovery
- Sharing resources and building skills Building community and relationships
- Leading recovery groups
- Mentoring and setting goals

Peer support roles:

- Providing services and/or training
- Supervising other peer workers
- Developing resourcesAdministering programs or agencies
- Educating the public and policymakers

28



29

Treatment Provider Information on Substance Use Disorders (SUDs)

The Montana DPHHS has a very intuitive SUDs treatment provider location website with an interactive map. The webpage is titled:

Substance Use Disorder Providers by Level of Care

Available at:

https://dphhs.mt.gov/amdd/SubstanceAbuse/TreatmentProviderInformation

- -

	Conclusion
	Please visit our website:
	http://health.msuextension.org/opioid_misuse.html
	Access to all five modules and PowerPoints
	Access to the Native American Toolkit
	Access to informational and recovery story videos
•	Print/download educational resources
•	Order a medication disposal pouch (while supplies last)
	ou have any questions, please email our program director Barbara Allen Ilen@montana.edu
	and the second s
-	
	ntana Department of Public Health and Human Services website: ps://dphhs.mt.gov/opioid/
WTAT	IA EXTENSION

References

Beth Connolly, & & Vanessa Baaklini. (2021, January 21). Primary Care Providers Can Help Steer People to Opioid Addiction Treatment. The Pew Charitable Trusts. https://www.pewtrusts.org/en/research-and-analysis/articles/2021/01/25/primarycare-providers-can-help-steer-people-to-opioid-addiction-treatment.

Centers for Disease Control and Prevention. (2019, May 22). Medication-Assisted Treatment for Opioid Use Disorder (2019-133). Centers for Disease Control and Prevention. <u>https://www.cdc.gov/niosh/docs/wp-solutions/2019-133/default.html</u>.

Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (US): 2005. (Treatment Improvement Protocol (TP) Servies, No. 33. (Dapter 2. History of Medication-Assisted Treatment for Opioid Addiction. Available from: https://www.ncbi.nlm.nih.gov/books/NBK64157/

Dunbar, E., Brennan, A., & Grocke, M. 2020. Stigma Free Addictions Terminology for Montanans. MontGuide. MT202013HR. Montana State University Extension.

Medication-Assisted Treatment (MAT). SAMHSA. (n.d.). https://www.samhsa.gov/medication-assisted-treatment.

[Partnership to End Addiction]. (2013, June 17) Medication-Assisted Treatment Overview: Naltrexone, Methadone & Suboxone I The Partnership [Video]. YouTube. <u>https://www.youtube.com/watch?v=tMusvDyoIRI</u>

[Psych Hub]. (2019, April 16) Medication Assisted Treatment [Video]. YouTube. https://www.youtube.com/watch?v=iWnrUCWY6AM

32

MONTANA EXTENSION

References

Screening, Brief Intervention, and Referral to Treatment (SBIRT). SAMHSA. (n.d.). https://www.samhsa.gov/sbirt.

Substance Abuse and Mental Health Services Administration. (2011, February 23). Recovery-Oriented Systems of Care (ROSC) Resource Guide.

What Is Integrated Behavioral Health Care (IBHC)? The Academy. (n.d.). https://integrationacademy.ahrq.gov/products/behavioral-health-measures-atlas/what-is-ibhc.

Zwick, J., Appleseth, H. & Arndt, S. Stigma: how it affects the substance use disorder patient. Subst Abuse Treat Prev Policy 15, 50 (2020). https://doi.org/10.1186/s13011-020-00288-0

MONTANA SANT UNIVERSITY EN